

MOLECULAR AUTOIMMUNITY

MOLECULAR AUTOIMMUNITY

Edited by

NORMAN TALAL, MD

*Department of Medicine, Division of Clinical Immunology,
The University of Texas Health Center at San Antonio, Texas, USA*



ACADEMIC PRESS

Harcourt Brace Jovanovich Publishers

London San Diego New York
Boston Sydney Tokyo Toronto

ACADEMIC PRESS LIMITED
24-28 Oval Road
London NW1 7DX

United States Edition published by
ACADEMIC PRESS INC.
San Diego, CA 92101

Copyright © 1991 by
ACADEMIC PRESS LIMITED, except Chapters 7 and 17

All Rights Reserved

No part of this book may be reproduced in any form by photostat, microfilm, or any other means, without written permission from the publishers

This book is printed on acid-free paper

A catalogue record for this book is available from the British Library

ISBN 0-12-682348-0

Typeset by Photo-graphics, Honiton, Devon
and printed in Great Britain by Galliard (Printers) Ltd, Great Yarmouth, Norfolk

Contributors

Grant J. Anhalt Department of Dermatology, The Johns Hopkins Medical Institution, 600 North Wolfe Street, Baltimore, MD 21205, USA

Wilhelm K. Aicher Department of Microbiology, University of Alabama at Birmingham, University Station, Birmingham, AL 35294, USA

Frank C. Arnett Division of Rheumatology, Department of Internal Medicine, The University of Texas Medical School at Houston, PO Box 207078, Houston, TX 77030, USA

Jean-François Bach Department de Nephrologie, de l'Hôpital Necker, 161 rue de Sevres, Paris 15e, France

Barry Benacerraf Department of Pathology, Harvard Medical School, Building D2 Room 453, 25 Shattuck Street, Boston, MA 02115, USA

Marcia A. Blackman Department of Medicine, Division of Basic Immunology, Howard Hughes Medical Institute at Denver, Denver, CO 80206, USA

Christian Boitard Department de Nephrologie, de l'Hôpital Necker, 161 rue de Sevres, Paris 15e, France

Dennis A. Carson Department of Medicine, University of California at San Diego, San Diego, CA 92093, USA

Pojen P. Chen Department of Medicine, University of California at San Diego, San Diego, CA 92093, USA

Irun R. Cohen Department of Cellular Biology, The Weizman Institute of Science, Rehovot, Israel

Thomas Dyrberg Novo Nordisk, Novo Alle, 2880 Bagsvaerd, Denmark

Renate E. Gay Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, THT 443, Birmingham, AL 35294, USA

Steffen Gay Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, THT 443, Birmingham, AL 35294, USA

Howard M. Grey CYTEL, 11099 North Torrey Pines Road, La Jolla, CA 92037, USA

Diane E. Griffin Departments of Medicine and of Neurology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA

David A. Hafler Division of Neurology, Department of Medicine, Center for Neurological Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA

Toshio Hirano Division of Molecular Oncology, Biomedical Research Centre, Osaka University Medical School, 4-3-57 Ngkanoshima, Kita-ku, Osaka 350, Japan

Chaim O. Jacob Syntex Research, R7-201, 3401 Hillview Avenue, Palo Alto, CA 94303, USA

John W. Kappler Departments of Microbiology, Immunology and Medicine, University of Colorado Health Sciences Center, Denver, CO 80206, USA

Tadamitsu Kishimoto Division of Immunology, Institute of Molecular & Cellular Biology, Osaka University, 1-3 Yamadaoka, Suita, Osaka 565, Japan

Robert G. Lahita St Luke's Roosevelt Columbia Hospital Center, Amsterdam Avenue at 114th Street, New York, NY 10025, USA

Alan G. Lamont Immunology Limited, Cambridge Science Park, Milton Road, Cambridge, CB4 4GN, UK

Philippa Marrack Howard Hughes Medical Center at Denver, 1400 Jackson Street, Denver, CO 80206, USA

Makoto Matsui Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Hugh O. McDevitt Departments of Microbiology and Immunology and Medicine, Fairchild Building, Stanford University, D-345, Stanford, CA 94305, USA

H.M. Moutsopoulos Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina 45110, Greece

Kathrin Muegge Biological Carcinogenesis and Development Program, PRI/Dyn Corp, NCI-Frederick Cancer Research & Development Center, P.O. Box B, Frederick, MD 21702, USA

Joost J. Oppenheim Laboratory of Molecular Immunoregulation, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD 21701, USA

Michael F. Powell Genentech Inc., 460 Pt San Bruno Blvd, South San Francisco, CA 94080, USA

Thomas T. Provost Department of Dermatology, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21205, USA

Morris Reichlin Department of Medicine, University of Oklahoma School of Medicine, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73105, USA

Noel R. Rose Department of Immunology and Infectious Diseases, 615 North Wolfe Street Room 4013, Baltimore, MD 21205, USA

Alessandro Sette Cytel, 11099 North Torrey Pines Road, La Jolla, CA 92037 USA

Gregor Stransky Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, THH 443, Birmingham, AL 35294, USA

Norman Talal Division of Clinical Immunology, The University of Texas, Health Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7874, USA

Andreas Trabandt Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, THH 443, Birmingham, AL 35294, USA

A.G. Tzioufas Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina 45110, Greece

John E. Volanakis Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Station THH 437, Birmingham, AL 35294, USA

Howard L. Weiner Center for Neurological Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA

John B. Winfield Thurston Arthritis Research Center, Division of Rheumatology and Immunology, The University of North Carolina, 932 Faculty Office Building 231h CB# 7280, Chapel Hill, NC 27599, USA

David Wofsy University of California, 4150 Clement Street, San Francisco, CA 94121, USA

Preface

In 1977 I edited a book for Academic Press entitled *Autoimmunity: Genetic, Immunologic, Virologic, and Clinical Aspects*. There were 23 chapters written by outstanding scientists and physicians working in the field of autoimmune diseases. Four individuals who contributed to that book are also represented here although their topics are different. The study of autoimmunity has become more molecular over the last decade. This molecular approach as well as new therapeutic possibilities are emphasized in the current volume. I thank the contributors for their effort and timely preparation of manuscripts, and also express appreciation to the excellent staff at Academic Press.

NORMAN TALAL

Contents

| | |
|---|-----|
| <i>List of contributors</i> | v |
| <i>Preface</i> | ix |
| 1 Overview and introduction <i>B. Benacerraf</i> | 1 |
| Part I: Genetic and immunologic factors | |
| 2 Genetic predisposition to autoimmune diseases: the contribution of the major histocompatibility complex <i>Chaim O. Jacob and Hugh O. McDevitt</i> | 7 |
| 3 Immunogenetics of the connective tissue diseases <i>Frank C. Arnett</i> | 31 |
| 4 Antibodies to RNA proteins in systemic lupus erythematosus: the significance of paired immune responses <i>Morris Reichlin</i> | 51 |
| 5 Molecular and genetic studies of human autoantibodies <i>Pojen P. Chen and Dennis A. Carson</i> | 65 |
| 6 Molecular genetics of complement and autoimmune diseases <i>John E. Volanakis</i> | 81 |
| 7 Interferon gamma and tumor necrosis factor in autoimmune disease models: implications for immunoregulation and genetic susceptibility <i>Chaim O. Jacob and Hugh O. McDevitt</i> | 107 |

| | | |
|----|---|-----|
| 8 | T cell tolerance <i>Marcia A. Blackman, John W. Kappler and Philippa Marrack</i> | 127 |
| 9 | IL-1 in autoimmunity <i>Kathrin Muegge and Joost J. Oppenheim</i> | 153 |
| 10 | Interleukin-6 and autoimmune diseases <i>Toshio Hirano and Tadimitsu Kishimoto</i> | 177 |

Part II: Pathogenic mechanisms

| | | |
|----|--|-----|
| 11 | Molecular mimicry in autoimmunity <i>Thomas Dyrberg</i> | 197 |
| 12 | Stress proteins: critical elements at the interface of host defense and autoimmunity <i>John B. Winfield</i> | 205 |
| 13 | Cellular and molecular basis of rheumatoid joint destruction <i>Andreas Trabandt, Renate E. Gay, Gregor Stransky, Wilhelm K. Aicher and Steffen Gay</i> | 233 |
| 14 | Virus-induced autoimmunity <i>Noel R. Rose and Diane E. Griffin</i> | 247 |
| 15 | Insulin-dependent diabetes mellitus: an autoimmune disease <i>Christian Boilard and Jean-François Bach</i> | 273 |
| 16 | Sjögren's syndrome: a model to study autoimmunity and lymphoid malignancy <i>H.M. Moutsopoulos, A.G. Tzioufas and Norman Talal</i> | 319 |
| 17 | Autoimmune skin diseases: immunopathogenic, immunogenetic and molecular considerations <i>Grant J. Anhalt and Thomas T. Provost</i> | 341 |
| 18 | Neurologic aspects of autoimmunity <i>Makoto Matsui, David A. Hafler and Howard L. Weiner</i> | 359 |
| 19 | Sex hormones and the immune system <i>Robert G. Lahita</i> | 385 |

Part III: New therapeutic possibilities

| | | |
|----|--|-----|
| 20 | Treatment of autoimmunity with monoclonal antibodies <i>David Wofsy</i> | 405 |
|----|--|-----|

| | | |
|----|--|-----|
| 21 | The MHC antagonist approach in autoimmunity <i>Alan G. Lamont, Howard M. Grey, Michael F. Powell and Alessandro Sette</i> | 425 |
| 22 | The immunological homunculus and autoimmune disease <i>Irvin R. Cohen</i> | 437 |
| | <i>Index</i> | 455 |

Overview and Introduction

B. BENACERRAF

Dana-Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston, MA, USA

Considerable progress has been made since autoimmune diseases were recognized, several decades ago, as a distinct pathogenic entity highly deserving of intense investigation. Much of our insight in the pathogenesis of these diseases has depended upon a thorough analysis and detailed understanding of the basic mechanisms of immunity and self-tolerance. It has been clearly established that T cell tolerance to self proteins is the result of clonal deletion during thymic differentiation. However, the precise cellular interactions whereby the thymic repertoire is selected and potentially autoreactive T cell clones are deleted have not been identified as yet. Our understanding of this process is unfortunately still very fragmentary and intense investigations in many laboratories are directed to clarify our knowledge of self-tolerance.

This volume addresses many aspects of the complex phenomena which are the basis of autoimmunity with the help of the modern technologies of genetics, cellular immunology and virology and extends the application of this basic information to an analysis of autoimmune pathogenesis at the clinical level.

The ability to differentiate self and non-self, which is the basis of the prevention of autoimmunity, depends on the complex regulatory mechanisms which govern T cell immunity to protein antigens.

It is well-established that foreign protein antigens need to be processed by antigen presenting cells (APCs) to generate the immunogenic peptides capable of interacting with autologous molecules of the major histocompatibility complex (MHC) for these complexes to be recognized by the T cell receptor (Benacerraf, 1978; Babbitt *et al.*, 1985; Unanue and Allen, 1987). The APCs process exogenous autologous and foreign proteins in an identical manner. There is increasing evidence, however, that the proteins synthesized

by an antigen presenting cell are handled differently than ingested proteins and that the peptides generated are associated preferentially with class I MHC molecules. The MHC molecules do not have the capacity to discriminate between the peptides generated from self and foreign proteins and are able to bind indifferently both types of peptides (Townsend *et al.*, 1986; Lorenz and Allen, 1988; Rothbard and Taylor, 1988). The development of autoimmunity is prevented by a mechanism whereby during thymic differentiation those T cell clones with receptors for autologous processed peptides presented in the context of self MHC molecules are deleted (Kappler *et al.*, 1988; Teh *et al.*, 1988) upon interaction with these complexes.

It is essential, therefore, that autologous proteins be processed identically in the course of tolerance induction in the thymus and later in the adult to avoid the generation of autoimmunity to autologous proteins.

Although the precise nature of antigen processing is not well-understood and is the subject of intense investigation in numerous laboratories, it is generally accepted that its mechanism involves primarily: (1) the unfolding of the protein, (2) the generation of peptides with hydrophobic and sometimes amphipathic sequences, and (3) often, but not always the digestion by proteolytic enzymes (Buus *et al.*, 1987; DeLisi and Berzofsky, 1985). Proteins can be similarly processed *in vitro*, denatured to expose hidden determinants, and digested to generate immunogenic fragments capable of binding to MHC molecules on fixed APCs and to stimulate T cells (Shimonkevitz *et al.*, 1984).

While writing the introduction to this volume I recalled an observation which we made many years ago in our laboratory (McCluskey *et al.*, 1962; Benacerraf, 1965) that may have identified an important molecular mechanism for the pathogenesis of autoimmunity, when considered in the context of our present understanding of the processing and presentation requirements for the generation of T cell immunity to protein antigens. We observed that whereas guinea-pigs did not respond to immunization with their own autologous gammaglobulins, they readily developed strong cellular immunity, manifested by skin reactivity, when immunized and tested with the same autologous protein which had been subjected to any of various forms of physical denaturation by heat, alkali or urea. In the light of our present knowledge of processing of and tolerance induction to self proteins in the thymus, these experiments indicate that the immune system is only tolerant to the determinants generated from autologous proteins processed in the standard manner by autologous APCs. Therefore, we are potentially vulnerable to the development of autoimmune responses to other determinants in autologous proteins, which can be generated either by some form of denaturation or alternative digestion by different proteolytic enzymes.

REFERENCES

- Babbitt, B.P., Allen, P.M., Matsueda, G., Haber, E. and Unanue, E. (1985). *Nature* **317**, 359–61.
- Benacerraf, B. (1965). *Ann. N.Y. Acad. Sci.* **165**, 124–6.
- Benacerraf, B. (1978). *J. Immunol.* **120**, 1809–12.
- Buus, S., Sette, A. and Grey, H.M. (1987). *Immunol. Rev.* **98**, 115–41.
- DeLisi, C. and Berzofsky, J.A. (1985). *Proc. Natl. Acad. Sci. U.S.A.* **82**, 7048–52.
- Kappler, J.W., Uwe, S., White, J. and Marrack, P.C. (1988). *Nature* **332**, 332–40.
- Lorenz, R.G. and Allen, P.M. (1988). *Proc. Natl. Acad. Sci. U.S.A.* **85**, 5220–3.
- McCluskey, R.T., Miller, F. and Benacerraf, B. (1962). *J. Exp. Med.* **115**, 253–73.
- Rothbard, J. and Taylor, W.R. (1988). *EMBO J.* **7**, 93–100.
- Shimonkevitz, R., Colón, S., Kappler, J.W., Marrack, P. and Grey, H.M. (1984). *J. Immunol.* **133**, 2067–74.
- Teh, H.S., Kisielow, P., Scott, B., Kishi, H., Uematsu, Y., Bluthmann, H. and von Boehmer, H. (1988). *Nature* **335**, 229–33.
- Townsend, A.R.M., Rothbard, J., Gotch, F.M., Bahadur, G., Wraith, D. and McMichael, A.J. (1986). *Cell* **44**, 959–68.
- Unanue, E.R. and Allen, P.M. (1987). *Science* **236**, 551–7.

Part I

Genetic and Immunologic Factors

